235 results about "Pharmaceutical Excipient" patented technology

The invention relates to the technical field of biological medicine, in particular to a ferroptosis inhibition type phospholipid-like material and application thereof. The ferroptosis inhibition type phospholipid-like material is one of the following structural general formulas (1)-(5). The biomimetic phospholipid-like ferroptosis inhibitor has a long retention characteristic in main positions (cell membranes, endoplasmic reticulum and other organelle membranes) of cell ferroptosis, so that the ferroptosis inhibition efficiency is remarkably improved. The novel phospholipid-like material not only can be used as an active drug molecule, but also can be used as a pharmaceutic adjuvant for constructing drug delivery carriers such as lipidosome and micelle and implant coatings, and is suitable for various administration routes such as oral administration, injection and local administration. The novel biomimetic ferroptosis inhibitor can efficiently relieve cell ferroptosis and has a wide application prospect in the field of treating or retarding ferroptosis-related diseases.

Provided herein are pharmaceutical compositions comprising a compound of having Formula I as described in this disclosure, or a pharmaceutically acceptable salt thereof, and optionally one or more pharmaceutical excipients, wherein the composition is in a unit dosage form; and methods for treating cancer modulated by HER2 in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition or a compound having Formula II as described in this disclosure, or a pharmaceutically acceptable salt thereof, and optionally one or more additional therapeutic agents.

The invention belongs to the technical field of biological fermentation, and particularly relates to a preparation method and application of a high-activity antioxidant product based on hericium erinaceus-hawthorn solid state fermentation. Activating the strain to prepare a seed solution; adding hawthorn into the rice solid culture medium, inoculating hericium erinaceus, performing constant-temperature culture, drying a fermentation product to constant weight at normal temperature and normal pressure after the culture is finished, crushing, and sieving for later use. The antioxidant effect of the fermentation product is comprehensively evaluated and verified through a systematic in-vitro chemical antioxidant experiment (ABTS < + >, DPPH free radical and hydroxyl free radical scavenging) and an in-vivo zebra fish oxidative stress model, and solid data support is provided for application of the fermentation product in healthy products. The resource high-value utilization way of the hawthorn and the hericium erinaceus is widened, and a technical scheme and a product prototype are provided for developing novel food raw materials, health-care products or medicine auxiliary materials with definite antioxidant functions.

Disclosed in the present invention are a preparation method for a brain-targeting agomelatine nasal spray micelle and use thereof, which belong to the technical field of pharmaceutical formulations. According to the present invention, an injectable pharmaceutical excipient polyethylene glycol (15)-hydroxystearate (HS15) is taken as a carrier material, HS15 and agomelatine are dissolved in an organic solvent, and the resulting solution is subjected to rotary evaporation under reduced pressure to form a uniform film, which, upon hydration, forms an agomelatine micelle solution capable of being sprayed nasally for treating depression and insomnia. According to the present invention, the problem of low oral bioavailability of agomelatine due to poor solubility, serious first pass effect of hepar, difficulty in penetrating a blood-brain barrier, etc., is solved. The micelle structure constructed in the present invention is quickly delivered into the brain after nasal administration, and it is stable in cerebrospinal fluid and can achieve slow release of the drug, thereby improving the intracerebral bioavailability of the drug and achieving high brain targeting property and low systemic toxic and side effects. The micelle structure has good clinical application value and market prospects.

The invention provides a briracetam sustained-release pharmaceutical composition as well as a preparation method and application thereof. The pharmaceutical composition comprises a pharmaceutical active ingredient and a pharmaceutical excipient, wherein the pharmaceutical excipient is selected from one or more of a framework material, a disintegrating agent, a swelling agent, an adhesive, a filler and a lubricant. The briracetam sustained-release pharmaceutical composition disclosed by the invention is good in sustained-release effect, stable in release speed and small in side effect, the medicine taking frequency is reduced, and the compliance of a patient is improved; the retention time of the medicine in the stomach is prolonged, so that the medicine is continuously released in the stomach and is absorbed at the upper end of the small intestine, the effect of continuously taking effect for 24 hours is achieved, the plasma concentration is stable, and the adverse reaction is small; a patient is prevented from randomly interrupting medication, and disease relapse and malignant complication development are prevented; the medicine is few in administration times, convenient to take and small in toxic and side effects.

A pharmaceutical composition or a pharmaceutical preparation, the pharmaceutical composition or the pharmaceutical preparation comprising a therapeutically effective amount of an active ingredient M and a pharmaceutical excipient, the active ingredient M being selected from a compound of general formula (I) or a stereoisomer, a tautomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or eutectic thereof, the pharmaceutical composition or the pharmaceutical preparation comprises 1-600 mg of an active ingredient M. The invention also relates to application of the pharmaceutical composition or the pharmaceutical preparation in preparation of related medicines for treating cancers.

The invention belongs to the field of pharmaceutical preparations. The invention relates to a novel dosage form of an isavuconazole sulfate freeze-dried tablet, and a prescription and a process for preparing the isavuconazole sulfate freeze-dried tablet by adopting a freeze-drying method. The isavuconazole sulfate freeze-dried tablet is prepared from isavuconazole sulfate serving as a main drug and pharmaceutic adjuvants. Water is not needed during taking, and the tablet can be rapidly disintegrated after being put in the mouth and is suitable for patients with dysphagia such as old people and children; the production process of the isavuconazole sulfate freeze-dried orally disintegrating tablet is simple in technology, easy to control and suitable for industrial production.

This invention discloses an energy-saving control system for drying equipment based on multidimensional factor analysis, belonging to the field of intelligent control technology. The system includes: interactively obtaining the pre-drying material characteristics of the pharmaceutical excipients to be dried; pre-constructing a material drying optimization space; locating initial drying control parameters; obtaining multiple sets of equipment parameter adjustment values ​​mapped to multiple drying stages; performing drying simulations on the pharmaceutical excipients to be dried using stage moisture content as a constraint, obtaining multiple sets of drying times, multiple sets of equipment energy consumption, and multiple sets of excipient loss rates; obtaining a target drying control array; and running the drying equipment to perform low-energy drying of the pharmaceutical excipients to be dried. This invention solves the technical problems of existing energy-saving control systems for drying equipment, which rely on fixed parameters and are difficult to accurately match the changes in the characteristics of different pharmaceutical excipients, leading to increased energy consumption and insufficient drying quality and efficiency of pharmaceutical excipients. It achieves the technical effects of effectively reducing energy consumption, improving drying efficiency, and enhancing product quality stability.

The invention provides a probiotic fermentation and bacterial powder compound addition chewable tablet and a preparation method thereof, and belongs to the technical field of microorganisms, the preparation method comprises the following steps: respectively adding water into apple peel, cerasus humilis fruits and aronia melanocarpa fruits, pulping, and mixing in proportion to obtain mixed fruit pulp; a mixed bacterium solution of lactobacillus plantarum LNJ-HQ-01 and lactobacillus fermentum BNCC194390 is added into the mixed fruit pulp, and fermentation is performed; freeze-drying and grinding the fermented fruit pulp to obtain freeze-dried fruit powder; the preparation method comprises the following steps: respectively activating lactobacillus plantarum LNJ-HQ-01, lactobacillus acidophilus BNCC186447 and lactobacillus rhamnosus ATCC7469, performing enlarged culture, taking bacterial sludge, uniformly mixing the bacterial sludge with a freeze-drying protective additive, and performing freeze-drying to obtain freeze-dried bacterial powder; and uniformly mixing the fruit powder, the freeze-dried bacterial powder and the medicinal auxiliary materials, and tabletting to obtain the probiotic chewable tablets. The probiotic chewable tablet is high in dietary fiber content, effective calcium content and total phenol content, high in oxidation resistance and suitable for calcium supplement of special groups such as diabetics and the like.

The invention relates to the technical field of analytical chemistry detection, in particular to a method for determining trace nitrite in pharmaceutic adjuvants.The method comprises the steps that an acetonitrile solution, a potassium hydroxide solution, a phosphate buffer solution, a sulfuric acid solution, a 2, 3-diaminonaphthalene solution and a reference substance working solution are provided; the method comprises the following steps: preparing a standard curve solution and a test sample solution, and carrying out ultra-high performance liquid chromatography-tandem mass spectrometry analysis detection: respectively carrying out sample injection detection on the test sample solution and the prepared standard curve solutions with different concentrations under preset chromatographic conditions and mass spectrometry conditions, recording detection results of the standard curve solutions with different concentrations to make a standard curve, and calculating the content of nitrite in the test solution by adopting a standard addition method according to the standard curve and the detection result of the test solution. The method disclosed by the invention can be used for rapidly determining trace nitrite in a drug sample, and can be used for determining the trace nitrite in pharmaceutical adjuvants and detecting the nitrite in drugs.

Described herein is a computer-implemented method for training a machine learning model for predicting one or more physiochemical properties of a nanoparticle. In some instances, the method includes receiving a set of data including nanoparticles, generating a descriptor and fingerprint for each nanoparticle in the set of data, creating a plurality of sets of training data and a plurality of sets of test data, training a machine learning model of an artificial intelligence (AI) system using the plurality of sets of training data, and predicting a property of the drug-excipient pair of the plurality of sets of test data based on drug-excipient pairs and property values of each drug-excipient pair of the plurality of sets of training data. Also described herein are excipients conjugated to a polyethylene glycol moiety, or pharmaceutically acceptable salts thereof. In some instances, the excipients may be used to form nanoparticles with a therapeutic compound.

The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.

The invention discloses an aromatic propionic acid derivative as well as a preparation method, a pharmaceutical composition and application thereof. The invention specifically discloses a compound shown in a formula (I) or pharmaceutically acceptable salt thereof. The invention further discloses a pharmaceutical composition which comprises the compound shown in the formula (I), pharmaceutically acceptable salt of the compound and pharmaceutic adjuvants. The invention also discloses application of the compound as shown in the formula (I), the pharmaceutically acceptable salt of the compound or the pharmaceutical composition in preparation of drugs, and the drugs have GPR40 receptor agonistic activity and have one or more of the advantages of good activity, high targeting property, low toxicity and the like. # imgabs0 #

This utility model discloses a drying and sealing storage chamber for pharmaceutical excipients, including a chamber body and a storage rack. The top of the chamber body has two slots, each with a drying frame inserted into its inner side. Each drying frame has an opening at its top and a movable plate is detachably connected via bolts. The left and right drying frames are fixedly connected by a lifting frame. Two partitions are fixedly connected to the inner side of the chamber body, each partition having three ventilation slots on its surface. A fan is installed inside each ventilation slot. This utility model, by providing a detachable drying frame at the top of the chamber body, combined with the lifting frame, allows for complete removal and replacement of the desiccant without opening the chamber body. This avoids external environmental interference with the internal drying process. Compared to traditional fixed drying structures, it achieves flexible switching between drying and ventilation, improving operational efficiency.

A tizanidine liquid preparation and use of the tizanidine liquid preparation in the preparation of a medicament for treating muscle spasm, wherein the tizanidine liquid preparation comprises an active ingredient, a stabilizing agent and other pharmaceutical excipients, wherein the active ingredient is one or more of tizanidine or a pharmaceutically acceptable salt, solvate and hydrate thereof.

The invention discloses a carrier cooperation system, application and a preparation method of a dihydrocodeine tartrate tablet, the carrier cooperation system comprises a mesoporous silica carrier and a hydroxypropyl trimethyl ammonium chloride chitosan modification layer, the surface of the mesoporous silica carrier is modified by silicon hydroxyl, and the hydroxypropyl trimethyl ammonium chloride chitosan modification layer is adsorbed in a pore channel of mesoporous silica. A mesoporous silica carrier modified by hydroxypropyl trimethyl ammonium chloride chitosan is formed; the silicon hydroxyl of the mesoporous silica carrier and the carboxyl of the active pharmaceutical ingredient form a hydrogen bond, and the quaternary ammonium group of the hydroxypropyl trimethyl ammonium chloride chitosan modified layer and the active pharmaceutical ingredient containing the tertiary amine group form an electrostatic complexing effect; according to the application of the carrier synergistic system in preparation of the abuse-preventing dihydrocodeine tartrate tablet, the tablet contains the carrier synergistic system, 6.67%-10.0% of dihydrocodeine tartrate and pharmaceutic adjuvants; the invention further discloses a specific preparation method, and the double effects of abuse prevention and slow release are synchronously achieved.

The application discloses a NO donor type ligustrazine derivative, a preparation method, a composition and application, and provides a NO donor type ligustrazine derivative and a preparation method thereof, and further provides a composition of different dosage forms prepared by mixing the NO donor type ligustrazine derivative or a pharmaceutically acceptable salt thereof and a pharmaceutical excipient, and application of the composition in preparation of a medicine for preventing or treating thromboembolic cardiovascular and cerebrovascular diseases and diseases caused by platelet aggregation.

According to the device for preparing and transferring the sterile liquid medicine, a preparation assembly is used for preparation and sterile treatment of auxiliary materials of the sterile liquid medicine, and the preparation assembly is arranged in a non-sterile environment; the first batching tank is used for preparing main raw materials of the sterile liquid medicine, is arranged in a sterile environment and is connected with the preparation assembly; the second batching tank is movably arranged in a non-sterile environment, the interior of the second batching tank is in a sterile state, and the second batching tank is connected with the first batching tank; the power source device can generate power, so that the sterile liquid medicine auxiliary materials enter the first batching tank after being subjected to configuration and sterile treatment, and carry the sterile liquid medicine main raw materials in the first batching tank to enter the second batching tank; the second mixing tank can be moved to a position close to the filling line and is in sterile butt joint with the filling line. According to the device, continuous supply of materials among different clean environments can be ensured, meanwhile, flexible matching in the sterile liquid medicine preparation process is achieved, and the sterility of the materials can be kept.

A fully dissolvable anticaries remineralization toothpaste for children and a preparation method thereof. The toothpaste has a three-layer composite structure: a dissolvable backing protective layer, an anticaries remineralization active layer, and a pH responsive layer. All components are food grade or pharmaceutical excipient grade, and completely dissolve within 10-30 minutes in the oral environment, without the need to remove after use. The active layer contains a "fluoride-nano hydroxyapatite-xylitol" ternary synergistic system, which can inhibit demineralization, promote remineralization, and inhibit cariogenic bacteria. The active layer also contains pH-responsive food colorants, which visually indicate the end of use through color changes. Formulas are designed for children aged 3-6 and 6-12, respectively, and the toothpaste can be cut along the preset line to fit different arch sizes. The invention solves the problems of poor use compliance, high risk of swallowing, and short residence time of active ingredients in existing children's anticaries products, and achieves safe, effective, and fun oral care for children.

The invention provides a medicine containing dronedarone. The medicine is used for targeted inhibition of stearoyl-CoA desaturase 1 (SCD1). The main component of the medicine is dronedarone or a pharmaceutically acceptable salt thereof, and the dronedarone or the pharmaceutically acceptable salt thereof is specifically combined with an SCD1 enzyme active site to inhibit the synthesis activity of catalyzing monounsaturated fatty acid and reduce the expression level of SCD1 protein in tumor cells, so that the dronedarone or the pharmaceutically acceptable salt thereof plays a role. According to the preparation method, dronedarone and pharmaceutic adjuvants are combined to prepare an oral preparation or an injection preparation, the oral preparation contains a quick release layer and a slow release layer, and the injection preparation is a freeze-dried powder injection. The optimization scheme comprises the steps of adjusting daily administration dosage (50-400mg) and using a specific carrier. Clinical application shows that dronedarone can significantly inhibit breast cancer cell proliferation and induce cell apoptosis, has a significant effect on treatment of fatty acid metabolism disorder diseases and proliferative diseases, and provides a new way for treatment of related diseases.

The present invention provides a traditional Chinese medicine taste-masking composition, which solves the contradiction between the large volume of traditional Chinese medicine compound preparations and the low drug loading of cyclodextrin, improves the taste-masking effect while reducing the amount of excipients used, and achieves synergistic effect. The traditional Chinese medicine taste-masking composition includes sulfobutyl-β-cyclodextrin and hydroxypropyl-β-cyclodextrin, and the mass ratio is 1:1. The composition also contains methyl-β-cyclodextrin and α-cyclodextrin; or it also contains polymerized-β-cyclodextrin, cationic-β-cyclodextrin, and methyl-β-cyclodextrin. The above-mentioned cyclodextrin and its derivatives are used as pharmaceutical excipients with low production costs and are suitable for industrial promotion. In addition, the present invention also provides the use of the traditional Chinese medicine taste-masking composition in Lanqin oral preparations. Compared with the commercially available Lanqin granules, the bitterness value of the Lanqin granules prepared by the present invention is reduced by 27% to 48%, and the Lanqin granules provided by the present invention have good hygroscopicity and stable quality.

The invention belongs to the technical field of medicines, and particularly relates to compound tylosin ophthalmic gel as well as a preparation method and application thereof. The invention relates to compound tylosin ophthalmic gel. The compound tylosin ophthalmic gel is prepared from tylosin tartrate, ganciclovir, pharmaceutic adjuvants and water, the pharmaceutic adjuvants comprise a thickening agent, a filling agent, a solubilizer, a bacteriostatic agent and a pH regulator. The compound tylosin ophthalmic gel disclosed by the invention takes effect quickly, has a remarkable treatment effect on feline conjunctivitis, has a lasting curative effect, and can still keep a relatively good drug effect after drug withdrawal.

The invention relates to the technical field of compound refining and purification, in particular to a high-purity low-endotoxin pharmaceutical adjuvant sodium dihydrogen phosphate dihydrate and a preparation method thereof. Comprising the following steps: mixing industrial-grade sodium dihydrogen phosphate dihydrate with pure water to form a first solution; a heavy metal complexing agent is added into the first solution, and a second solution is formed after heating and stirring reaction; prefabricated activated carbon is added into the second solution, and a third solution is formed after heating and stirring reaction; and filtering the third solution while hot, concentrating under reduced pressure until a crystal film appears in the solution, naturally cooling and crystallizing, and performing solid-liquid separation to obtain the high-purity low-endotoxin pharmaceutical adjuvant sodium dihydrogen phosphate dihydrate. After refining and purification, the purity is greater than 99 wt%, the content of heavy metals is not greater than 0.0005 wt%, the content of endotoxin is lower than 2.5 EU / g, and the pharmaceutical adjuvant level is reached.

The present disclosure provides high-load tablet formulations of AG10 or a pharmaceutically acceptable salt thereof. In some aspects, provided herein are table formulations of AG10 or a pharmaceutically acceptable salt thereof that include at least 40% or more AG10 by weight and at least one pharmaceutical excipient selected from one or more fillers, one or more binders, one or more disintegrants, and one or more lubricants.

The present invention provides a composition of nebivolol and amlodipine, comprising nebivolol, amlodipine and a pharmaceutical excipient. The nebivolol comprises one or more of nebivolol, a pharmaceutically acceptable salt thereof, and a solvate thereof. The amlodipine comprises one or more of amlodipine, a pharmaceutically acceptable salt thereof, and a solvate thereof. The pharmaceutical excipient is selected from one or more of a filler, a binder, a disintegrant, a lubricant, and a glidant. The composition does not contain a colorant and a film coating. The compound preparation of the present invention has good stability, and is beneficial to improving the antihypertensive efficacy, enhancing safety and tolerability, and reducing side effects. Compared to monotherapy, the present invention reduces the number of administered medications and improves the compliance of patients, is beneficial to improving the medication compliance of the elderly patients and individuals with dysphagia, maintains a stable plasma drug concentration, maintains long-term stable blood pressure in hypertensive patients, prevents the patients from discontinuing medication arbitrarily, and prevents disease recurrence and the progression of severe complications.

The invention discloses an application of sodium bicarbonate in preparation of a tumor immune drug enhancer. The molecular formula of the sodium bicarbonate is NaHCO3. Tumor necrosis factor alpha (TNF-alpha) is used as an anti-tumor drug to treat tumors, however, the anti-tumor efficacy of the TNF-alpha is unpredictable. It is proved that TNF-alpha activates a nuclear factor kappa B (nuclear factor kappa-light-chain-energy active B cells, NF-kappa B) signal channel, inflammatory response is enhanced, tumor cell growth is promoted, and the TNF-alpha can activate a nuclear factor kappa B (nuclear factor kappa-light-chain-energy active B cells (NF-kappa B) signal channel. Under the action of sodium bicarbonate, a TNF-alpha mediated NF-kappa B signal channel is inhibited, a TNF-alpha mediated receptor-interacting serine / threonine-protein kinase 1 (RIPK1) dependent Necroptosis signal channel is activated, and the death of tumor cells is caused, so that the TNF-alpha mediated receptor-interacting serine / threonine-protein kinase 1 (RIPK1) depends on the TNF-alpha mediated receptor-interacting serine / threonine-protein kinase 1 (RIPK1) and the TNF-alpha mediated receptor-interacting serine / threonine-protein kinase 1 (RIPK1). The prepared medicine contains a medicine excipient or a carrier allowed by a preparation. The invention develops new application of sodium bicarbonate in preparation of medicines for treating tumors. And the medicine is non-toxic to a human body after being administrated in a tumor body. Sodium bicarbonate can be used for preparing a reinforcing agent of TNF-alpha.

The present document describes a pharmaceutical excipient composition comprising a functionalized anionic polysaccharide having carboxyl groups complexed with an amino acid-divalent cation complex, monolithic solid dosage forms for dual rate release of an active pharmaceutical ingredient, comprising the pharmaceutical excipient composition and active pharmaceutical ingredients, as well as processes for preparing the pharmaceutical excipient composition.

The utility model relates to the technical field of granulator discloses a medicinal excipient granulating equipment, including granulating box and granulating roller, the inside upper portion of granulating box is longitudinally installed with two and each other is close to of granulating roller is set up, and the transmission connection of speed reducer motor installed on the outside surface of granulating box is set up with its front end granulating box, the top of granulating box is provided with the feed hopper that communicates with the inside of granulating box, and the inside of granulating box below granulating roller is longitudinally fixed with the mesh plate that is bent into the cylinder, and the top of mesh plate is provided with the upper mouth that communicates with its inboard. The utility model technical scheme is provided with the mesh plate of the cylinder below between two granulating rollers, and the excipient of flaky particle state can be through the upper mouth and fall into the inboard of mesh plate and be moved by the paddle, and the excipient of flaky particle state can be scattered in the indentation position finally after being moved by the paddle many times, ensure that flaky material is completely broken and avoid the larger force or action speed and make granule raw material be destroyed into powder again, ensure the quality of finished product.

Relates to a pharmaceutical composition of pyridinopyrazole derivatives and application thereof in medicine, the pharmaceutical composition comprises an active component A and a pharmaceutical excipient, the active component A is selected from a compound shown in a general formula (I) or a stereoisomer, a tautomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a co-crystal thereof, the pharmaceutical composition comprises 1-1200 mg of an active component A, and the content of the active component A is selected from 0.5%-99.0%. The invention also relates to application of the pharmaceutical composition in preparation of related medicines for treating cancers.

The invention discloses sunflower disc holocellulose, a preparation method and application of the sunflower disc holocellulose as a disintegrating agent, and belongs to the technical field of pharmaceutic adjuvants. The preparation method comprises the following steps: crushing sunflower heads, sieving, degreasing to obtain sunflower head powder, mixing the sunflower head powder with an alkali solution, and extracting; and bleaching the washed and dried filter residues, washing, drying, and modifying with a biological enzyme to obtain the sunflower disc holocellulose disintegrating agent. The disintegrant is prepared from agricultural wastes as raw materials through alkali extraction, bleaching, enzyme modification and other processes, the sunflower disc holocellulose is used as an efficient pharmaceutical adjuvant disintegrant, rapid disintegration of tablets such as orally disintegrating tablets and the like can be achieved, the disintegration effect can be equivalent to that of commercially available efficient disintegrants, and high-value utilization of the agricultural wastes is achieved. The prepared disintegrating agent is high in water absorption performance, good in expansion performance, good in biocompatibility and environment-friendly, and has important practical significance for fully utilizing biomass resources and solving the problem of medicine auxiliary material sources.